Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) CFO Andrew D. Dickinson sold 8,500 shares of the stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $91.96, for a total value of $781,660.00. Following the sale, the chief financial officer now owns 132,373 shares of the company's stock, valued at $12,173,021.08. This represents a 6.03 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Shares of GILD stock traded up $0.75 during trading hours on Tuesday, hitting $92.80. The company's stock had a trading volume of 6,123,645 shares, compared to its average volume of 7,064,540. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $98.90. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The stock has a market cap of $115.65 billion, a PE ratio of 1,022.78, a price-to-earnings-growth ratio of 2.38 and a beta of 0.18. The company has a 50 day moving average of $90.11 and a 200 day moving average of $79.86.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.58 by $0.44. The company had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. Gilead Sciences's revenue for the quarter was up 7.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.29 earnings per share. On average, sell-side analysts forecast that Gilead Sciences, Inc. will post 4.35 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 30th. Shareholders of record on Friday, December 13th will be issued a $0.77 dividend. The ex-dividend date is Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a yield of 3.32%. Gilead Sciences's payout ratio is currently 3,422.22%.
GILD has been the subject of a number of analyst reports. Citigroup began coverage on shares of Gilead Sciences in a report on Thursday, November 14th. They issued a "buy" rating and a $125.00 price target for the company. Royal Bank of Canada reaffirmed a "sector perform" rating and set a $84.00 price target on shares of Gilead Sciences in a research note on Wednesday, December 11th. JPMorgan Chase & Co. boosted their target price on Gilead Sciences from $100.00 to $105.00 and gave the company an "overweight" rating in a research report on Thursday, November 7th. BMO Capital Markets raised their price target on Gilead Sciences from $94.00 to $102.00 and gave the stock an "outperform" rating in a research note on Thursday, November 7th. Finally, Truist Financial increased their target price on Gilead Sciences from $83.00 to $97.00 and gave the stock a "hold" rating in a research note on Friday, November 8th. Twelve equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and four have assigned a strong buy rating to the stock. According to data from MarketBeat, Gilead Sciences currently has a consensus rating of "Moderate Buy" and a consensus target price of $96.43.
Read Our Latest Analysis on GILD
A number of large investors have recently modified their holdings of the business. nVerses Capital LLC purchased a new stake in Gilead Sciences during the 3rd quarter valued at about $25,000. Valued Wealth Advisors LLC increased its stake in shares of Gilead Sciences by 101.9% in the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 161 shares during the last quarter. Strategic Investment Solutions Inc. IL purchased a new position in Gilead Sciences during the second quarter worth about $33,000. Cedar Wealth Management LLC grew its position in Gilead Sciences by 51.6% in the second quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company's stock worth $32,000 after acquiring an additional 160 shares during the period. Finally, Financial Connections Group Inc. acquired a new position in Gilead Sciences in the second quarter valued at about $34,000. Hedge funds and other institutional investors own 83.67% of the company's stock.
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.